Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Monday July 8

-I, -I

MoPeA3o5o Recombinant yeast vaccine induces maturation of
human blood dendritic cell subsets
MA Barron N Blyveis, A C Stubbs, CC Wilson
(United States)
MoPeA3o51 Development of multivalent vaccines effective
against viruses from the B, C, and E subtypes
D Smith, M Daoust, F Gao, L Riddle, M Rodriguez,
J Good, S Lee, M Peterson, FSinangil,
P W Berman (United States)
MoPeA3o52 Prime/boost immunization approaches in rhesus
monkeys using replication-incompetent
adenovirus, modified vaccinia ankara (MVA)
virus, and DNA vaccines
J W Shiver, D R Casimiro, T Fu, X Liang, R K Evans,
M Davies, A Bett, M Chastain, S Dubey, D Freed,
Z Zhang, L Handt, W Schleif, E Emini
(United States)
MoPeA3o53 Immune responses in mice after rectal, vaginal
and percutaneousal application of HIV-DNA
vaccine
K Hamajima K Xin, K Okuda (lapan)
MoPeA3o54 Survey of anti-HIV T cell immune responses in
HIV-1 infected humans
JW Shiver, T Fu, D Mehrotra, S Dubey, D Freed,
T Evans, R Steigbigel, JJacobson, M Mulligan,
P Goepfert, S Kalams, C Rinaldo, C Kalinyak,
P Coplan, S Thaler, EA Emini (United States)
MoPeA3o55 Reactivity of anti-HIV T-cell immune responses to
different HIV-1 subtypes among HIV+ individuals
from Brazil, Thailand and the US
P Coplan1, A Nikas', E Kallas2, P Pitisuttithum3,
M Schechter2, P Puthavathana3, TM Fu1,
S Dubey1, D Freed', S Thaler, D Mehrotra,
J Condra, E Emini', I Shiver' (United States;
2Brazil; 3Thailand)
MoPeA3o56 Animal model testing of an HIV-1 envelope
vaccine candidate from the clinical R5 isolate
BXo8 using humanized genes and DNA
vaccination
L Vinner, E G T Wee2, S Patel2, T Hanke2,
S L Corbet', C Nielsen', H CJ Ertl3, A Fomsgaard1
(iDenmark; 2 United Kingdom; 3United States)
MoPeA3o57 Induction of anti-Tat immune response by
vaccination with an HSV-1 based replication
defective vector
P C Marconi A Bozac, E Berto, G Gardo, E Garaffa,
C Fortini, R Gavioli, R Manservigi, B Ensoli (Italy)
MoPeA3o58 CpG immuno stimulatory oligodeoxynucleotides
overcome a Th2 biased immune response for the
generation of Thi HIV-1 specific immunity
M Ayash-Rashkovsky', Z Bentwich, R B Moss2,
G Borkow (lsrael; 2 United States)
MoPeA3o59 Novel tailor-made synthetic block copolymers for
gene delivery for vaccine application
A Caputo, E Brocca-Cofano, A Castaldello,
R Gavioli, K Sparnacci, M Laus, L Tondelli,
B Ensoli (Italy)
MoPeA3o6o Immunogenicity of Modified Vaccinia Ankara and
Salmonella typhimurium producing an HIV
polyprotein in HLA-A2 transgenic mice
A Didierlaurent, I C Ramirez, M Esteban,
H AchaOrbea', I P Kraehenbuhl, I C Sirard'
(Switzerland; 2Spain)
MoPeA3o61 Lessons learned and issues related to HIV
vaccine development and availability
VP Thiamchai (Thailand)
MoPeA3o62 HIV vaccine awareness and willingness to

participate in HIV vaccine trials: a populationbased study, Rakai District, Uganda
N Kiwanuka (Uganda)

MoPeA3o63 Mucosal immunization with inactivated HIV-.1 -capturing nanospheres significantly induces vaginal
anti-HIV-1 IgA response in mice
K Hiraishi, TAkagi, M Ueno, M Adachi,
TSerizawa, M Akashi, M Kawamura, M Baba (apan)
MoPeA3o64 Protection against mucosal challenge with SHIV 89.6P
in rhesus macaques immunized with VSV-based
vaccine vectors expressing HIV-1 env and SIV- gag
M Egan, Z Israe, S Chong, N Rose, S Megati,
E Schadeck, A Masood, P Piacente, E Mishkin,
P Marx, S Udem, I Eldridge, I Rose (United States)
MoPeA3o65 Induction of a protective immune response
against R5-HIV-1 in hu-PBL-SCID mice by
immunization with autologous mature dendritic
cells pulsed with inactivated HIV-1
Y Tanaka A Yoshida, R Tanaka, M Nakamura,
N Yamamoto (Japan)
MoPeA3o66 Efficient CD8+ T cell response to the H IV-env V3
loop epitope from multiple isolates by a DNA
prime/vaccinia boost immunization regime
CE Gomez, FAbaitua, D Rodriguez',
CA Duarte2, M Esteban' (Spain; 2Cuba)
MoPeA3o67 Vaccines to block multiple sexually transmitted
infections: Immunogenicity and efficacy of
chimeric HIV-wart virus vaccines in macaques
C J Dale X S Liu, R De Rose, D F Purcell,
j L Anderson, YXu, G R Leggatt, I H Frazer,
S JKent (Australia)
MoPeA3o68 HIV-1 envelope complexes presenting stabilized
gp41 fusion intermediates as vaccine candidates
N R Kilgore, K Salzwedel, M Reddick, GP Allaway,
C T Wild (United States)
MoPeA3o69 Enhanced DNA prime-protein boost vaccines
induce potent and protective immune responses
against HIV-1
S W Barnett, I Srivastava', J Zur Megede', Y Lian,
G Otten', L Stamatatos, D Montefiori, M Lewis1,
S Engelbrecht2, E janse van Rensburg, G Widera,
D O'Hagan, J Polo, ] Ulmer, I Donnelly' (United
States; 2South Africa)
MoPeA3o7o Prime/Boost immunization schedules based on
influenza and vaccinia virus (VV) vectors (MVA
and WR) potentiate cellular immune responses
against HIV-env protein systemically and in the
genito-rectal draining lymph nodes
M M Gherardi, E Pirez]Jimdnez, I L Ndgera1,
D Rodriguez', A Garcda-Sastre2, P Palese,
M Esteban1 ('Spain; 2United States)
MoPeA3o71 Prime-boost vaccination for high level mucosal
and systemic cellular immune responses
A JRamsay, M Estcourt2, I A Ramshaw,
C Ranasinghe2 (United States; 2Australia)
MoPeA3o72 Identification of new HIV-1 derived CTL (cytotoxic
T lymphocyte) epitopic peptides using HLAB*o702+/+ H-2Kb-/- H-2Db-/- mice and validation
in HIV+ patients
S Cardinaud, M Fevrier, A Habel, PS Rohrlich,
Y Riviere, L Weiss, FA Lemonnie, P LangladeDemoyen (France; 2Austria)
MoPeA3o73 Alloimmunization and immune response of
simian macaques in an SIV challenge trial
MA Luscher, E Rakasz2, D I Watkins, Y Guan,
M Candido, I Tartaglia', M I Tremblay,
KS MacDonald (Canada; 2United States)
MoPeA3o74 Mucosal immunization with inactivated gpi2odepleted HIV-i (REMUNE) plus CpG ODN induces
potent immune responses in the genital tract and

protection against intravaginal challenge
N Dumais, IJiang', R B Moss2, H L Davis,
K L RosenthaP ('Canada; 2United States)
XIV International AIDS Conference BARCELONA - JULY 7-12

Monday

33